GILEAD AND ACHILLION INITIATE PHASE I HEPATITIS C TRIAL

Gilead Sciences and Achillion Pharmaceuticals announced that they have begun dosing patients in a Phase I study of GS 9132, also known as ACH-806. Gilead and Achillion are investigating GS 9132 for the treatment of hepatitis C.

The Phase I trial is a double-blind, randomized, placebo-controlled dose-escalation study. The goal of the trial is to evaluate the pharmacokinetics, tolerability and safety of single escalating doses of GS 9132 in healthy volunteers. The study will take place in the U.S. and will enroll approximately 20 subjects. As an investigational compound, GS 9132 has not yet been determined safe or efficacious in humans for its ultimate intended use.